RU2014148544A - Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей - Google Patents
Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей Download PDFInfo
- Publication number
- RU2014148544A RU2014148544A RU2014148544A RU2014148544A RU2014148544A RU 2014148544 A RU2014148544 A RU 2014148544A RU 2014148544 A RU2014148544 A RU 2014148544A RU 2014148544 A RU2014148544 A RU 2014148544A RU 2014148544 A RU2014148544 A RU 2014148544A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- poly
- composition
- starch
- weight
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 29
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 title claims abstract 9
- 206010057190 Respiratory tract infections Diseases 0.000 title claims abstract 3
- 239000002253 acid Substances 0.000 title claims abstract 3
- 208000020029 respiratory tract infectious disease Diseases 0.000 title claims abstract 3
- 229920002472 Starch Polymers 0.000 claims abstract 8
- 235000019698 starch Nutrition 0.000 claims abstract 8
- 239000008107 starch Substances 0.000 claims abstract 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000011859 microparticle Substances 0.000 claims abstract 6
- 229920000642 polymer Polymers 0.000 claims abstract 6
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 239000003960 organic solvent Substances 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 claims abstract 2
- 229940072056 alginate Drugs 0.000 claims abstract 2
- 229920000615 alginic acid Polymers 0.000 claims abstract 2
- 235000010443 alginic acid Nutrition 0.000 claims abstract 2
- 208000015181 infectious disease Diseases 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims abstract 2
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 239000002245 particle Substances 0.000 claims abstract 2
- 238000001694 spray drying Methods 0.000 claims abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1. Композиция, содержащая микрочастицы полиинозиновой-полицитидиловой кислоты (Poly(I:C)) и полимера-носителя, выбранного из крахмала, альгината, бланозы или дипальмитоилфосфатидилхолина (DPPC).2. Композиция по п. 1, отличающаяся тем, что указанный полимер-носитель представляет собой крахмал.3. Композиция по п. 1, отличающаяся тем, что микрочастицы Poly(I:C) и полимера-носителя получены посредством способа образования частиц, такого как способ распылительной сушки.4. Композиция по п. 1, отличающаяся тем, что соотношение Poly(I:C)/крахмал варьируется в диапазоне от 1/200 (вес./вес.) до 1/0,1 (вес./вес.).5. Композиция по п. 4, отличающаяся тем, что соотношение Poly(I:C)/крахмал составляет от 1/12 (вес./вес.) до 1/9 (вес./вес.).6. Композиция по п. 3, отличающаяся тем, что D50 микрочастиц варьируется в диапазоне от 0,1 микрометра до 200 микрометров.7. Композиция по п. 1, отличающаяся тем, что указанная композиция представляет собой жидкую композицию, содержащую органический растворитель.8. Композиция по п. 7, отличающаяся тем, что в основе органического растворителя лежат глицерин или этанол или их комбинация.9. Композиция по любому из пп. 1-8 для применения в медицине.10. Композиция по любому из пп. 1-8 для применения в лечении и/или предупреждении инфекций или простуды.11. Применение композиции по любому из пп. 1-8 для производства лекарственного препарата для предупреждения и/или лечения инфекций верхних дыхательных путей путем назального введения.12. Устройство, в частности система назальной доставки, содержащее композицию по любому из пп. 1-8.
Claims (12)
1. Композиция, содержащая микрочастицы полиинозиновой-полицитидиловой кислоты (Poly(I:C)) и полимера-носителя, выбранного из крахмала, альгината, бланозы или дипальмитоилфосфатидилхолина (DPPC).
2. Композиция по п. 1, отличающаяся тем, что указанный полимер-носитель представляет собой крахмал.
3. Композиция по п. 1, отличающаяся тем, что микрочастицы Poly(I:C) и полимера-носителя получены посредством способа образования частиц, такого как способ распылительной сушки.
4. Композиция по п. 1, отличающаяся тем, что соотношение Poly(I:C)/крахмал варьируется в диапазоне от 1/200 (вес./вес.) до 1/0,1 (вес./вес.).
5. Композиция по п. 4, отличающаяся тем, что соотношение Poly(I:C)/крахмал составляет от 1/12 (вес./вес.) до 1/9 (вес./вес.).
6. Композиция по п. 3, отличающаяся тем, что DV50 микрочастиц варьируется в диапазоне от 0,1 микрометра до 200 микрометров.
7. Композиция по п. 1, отличающаяся тем, что указанная композиция представляет собой жидкую композицию, содержащую органический растворитель.
8. Композиция по п. 7, отличающаяся тем, что в основе органического растворителя лежат глицерин или этанол или их комбинация.
9. Композиция по любому из пп. 1-8 для применения в медицине.
10. Композиция по любому из пп. 1-8 для применения в лечении и/или предупреждении инфекций или простуды.
11. Применение композиции по любому из пп. 1-8 для производства лекарственного препарата для предупреждения и/или лечения инфекций верхних дыхательных путей путем назального введения.
12. Устройство, в частности система назальной доставки, содержащее композицию по любому из пп. 1-8.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12166595.4 | 2012-05-03 | ||
EP12166595 | 2012-05-03 | ||
PCT/EP2013/059079 WO2013164380A1 (en) | 2012-05-03 | 2013-05-02 | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2014148544A true RU2014148544A (ru) | 2016-06-27 |
RU2650636C2 RU2650636C2 (ru) | 2018-04-16 |
Family
ID=48430695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014148544A RU2650636C2 (ru) | 2012-05-03 | 2013-05-02 | Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей |
Country Status (18)
Country | Link |
---|---|
US (3) | US9682096B2 (ru) |
EP (1) | EP2846767B1 (ru) |
JP (1) | JP6349304B2 (ru) |
KR (1) | KR102240042B1 (ru) |
CN (1) | CN104394846B (ru) |
AU (1) | AU2013255885C1 (ru) |
BR (1) | BR112014026957A8 (ru) |
CA (1) | CA2866230C (ru) |
CL (1) | CL2014002929A1 (ru) |
CO (1) | CO7101247A2 (ru) |
ES (1) | ES2911116T3 (ru) |
HK (1) | HK1203390A1 (ru) |
IN (1) | IN2014MN02359A (ru) |
MX (1) | MX2014013256A (ru) |
NZ (1) | NZ630040A (ru) |
RU (1) | RU2650636C2 (ru) |
SG (2) | SG10201607288VA (ru) |
WO (1) | WO2013164380A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IN2014MN02359A (ru) | 2012-05-03 | 2015-08-14 | Janssen R & D Ireland | |
KR20160072140A (ko) * | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
GB201415381D0 (en) * | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
KR20180004233A (ko) * | 2015-05-11 | 2018-01-10 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염의 예방 및/또는 치료를 위한 폴리이노신-폴리사이티딜산 (Poly (I:C)) 완두 전분 제형 |
CN112294757B (zh) | 2015-11-17 | 2024-02-13 | 亮点医疗有限责任公司 | 包含含有双链聚核糖核苷酸与聚亚烷基亚胺的复合物的粒子的医药组合物 |
KR20180105129A (ko) * | 2015-11-30 | 2018-09-27 | 노부스 테라퓨틱스, 인크. | 이과학적 예방 및 치료를 위한 조성물 및 방법 |
US20200060972A1 (en) | 2016-11-16 | 2020-02-27 | Janssen Sciences Ireland Unlimited Company | Formulations of polyinosinic acid and polycytidylic acid for the prevention of upper respiratory tract infections |
US10849921B2 (en) | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
CA3105281A1 (en) * | 2018-06-29 | 2020-01-02 | Xinfu (Beijing) Medical Technology Co., Ltd. | Complex for enhancing immune response |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8723846D0 (en) | 1987-10-10 | 1987-11-11 | Danbiosyst Ltd | Bioadhesive microsphere drug delivery system |
US5707644A (en) * | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
ATE154241T1 (de) | 1991-10-01 | 1997-06-15 | Takeda Chemical Industries Ltd | Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe |
GB9606188D0 (en) * | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
TW577759B (en) | 1997-04-18 | 2004-03-01 | Ipsen Pharma Biotech | Sustained release compositions in the form of microcapsules or implants and the process for their preparation |
CA2203843C (en) * | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
MA25590A1 (fr) * | 1998-09-14 | 2002-12-31 | Inhale Therapeutic Syst | Agent actif de delivraison de poudre seche |
EP1322291A1 (en) * | 2000-10-06 | 2003-07-02 | Jagotec Ag | Biodegradable microparticles for controlled release administration, with purified amylopectin-based starch of reduced molecular weight |
AU2003287332A1 (en) * | 2002-11-01 | 2004-06-07 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
US20070219149A1 (en) | 2003-08-11 | 2007-09-20 | The Research Foundation For Microbial Diseases Of Osaka University | Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity |
CA2548992A1 (en) | 2003-12-11 | 2005-08-11 | Vaxdesign Corporation | Immunotherapy compositions, method of making and method of use thereof |
CN101229378A (zh) | 2005-05-05 | 2008-07-30 | 国家淀粉及化学投资控股公司 | 用于送递活性剂的组合物 |
MX2007015639A (es) | 2005-06-08 | 2008-02-15 | Newbiomed Pika Pte Ltd | Adyuvante basado en acido poliinosinico-acido policitidilico. |
US20070166239A1 (en) * | 2006-01-13 | 2007-07-19 | Haixiang Lin | Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant |
GB0607534D0 (en) | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
DK2046740T3 (da) | 2006-07-22 | 2012-08-20 | Oxagen Ltd | Forbindelser med CRTH2-antagonistisk virkning |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
AR067997A1 (es) * | 2007-08-24 | 2009-10-28 | Novartis Ag | Compuestos organicos |
JP2009209086A (ja) * | 2008-03-04 | 2009-09-17 | Masami Moriyama | 粘膜投与型ワクチン |
UA90013C2 (ru) * | 2008-03-19 | 2010-03-25 | Давид Анатолійович Нога | Фармацевтическая композиция, содержащая инсулин, и способ его получения |
EP2116602A1 (en) | 2008-05-07 | 2009-11-11 | Institut Gustave Roussy | Combination products for treating cancer |
WO2010066203A1 (en) * | 2008-12-10 | 2010-06-17 | Anhui Zhongren Technology Co., Ltd. | Controlled releasing composition |
CN101491503A (zh) | 2008-12-17 | 2009-07-29 | 天津瑞普生物技术股份有限公司 | 一种用于宠物的聚肌胞滴丸及其制备方法 |
LT3098239T (lt) | 2008-12-22 | 2020-02-10 | Targimmune Therapeutics Ag | Į egfr nukreipiamas dvigrandis rnr vektorius, skirtas sisteminiam vėžio gydymui |
CN101757018A (zh) * | 2008-12-24 | 2010-06-30 | 天津瑞普生物技术股份有限公司 | 一种用于畜禽的聚肌胞干粉及其制备方法 |
US9603919B2 (en) | 2009-03-31 | 2017-03-28 | Japan As Represented By The Director-General Of National Institute Of Infectious Diseases | Method for prophylaxis of influenza using vaccine for intranasal administration |
EP2598145A1 (en) | 2010-07-28 | 2013-06-05 | Boehringer Ingelheim International GmbH | Pharmaceutical composition for treatment of respiratory and inflammatory diseases |
US8431155B1 (en) | 2012-04-30 | 2013-04-30 | Veroscience Llc | Bromocriptine formulations |
IN2014MN02359A (ru) | 2012-05-03 | 2015-08-14 | Janssen R & D Ireland | |
KR20160072140A (ko) | 2013-11-06 | 2016-06-22 | 얀센 사이언시즈 아일랜드 유씨 | 상기도 감염 치료용 폴리이노신산-폴리사이티딜산(폴리 (i:c)) 제형 |
-
2013
- 2013-05-02 IN IN2359MUN2014 patent/IN2014MN02359A/en unknown
- 2013-05-02 JP JP2015509432A patent/JP6349304B2/ja active Active
- 2013-05-02 WO PCT/EP2013/059079 patent/WO2013164380A1/en active Application Filing
- 2013-05-02 NZ NZ630040A patent/NZ630040A/en unknown
- 2013-05-02 CN CN201380023084.4A patent/CN104394846B/zh active Active
- 2013-05-02 CA CA2866230A patent/CA2866230C/en active Active
- 2013-05-02 BR BR112014026957A patent/BR112014026957A8/pt not_active Application Discontinuation
- 2013-05-02 ES ES13722334T patent/ES2911116T3/es active Active
- 2013-05-02 KR KR1020147028656A patent/KR102240042B1/ko active IP Right Grant
- 2013-05-02 AU AU2013255885A patent/AU2013255885C1/en active Active
- 2013-05-02 SG SG10201607288VA patent/SG10201607288VA/en unknown
- 2013-05-02 EP EP13722334.3A patent/EP2846767B1/en active Active
- 2013-05-02 SG SG11201406208QA patent/SG11201406208QA/en unknown
- 2013-05-02 US US14/398,573 patent/US9682096B2/en active Active
- 2013-05-02 RU RU2014148544A patent/RU2650636C2/ru active
- 2013-05-02 MX MX2014013256A patent/MX2014013256A/es unknown
-
2014
- 2014-10-15 CO CO14228077A patent/CO7101247A2/es unknown
- 2014-10-29 CL CL2014002929A patent/CL2014002929A1/es unknown
-
2015
- 2015-04-27 HK HK15104025.4A patent/HK1203390A1/xx unknown
-
2016
- 2016-06-13 US US15/180,603 patent/US9987300B2/en active Active
-
2018
- 2018-05-07 US US15/972,840 patent/US10485816B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104394846A (zh) | 2015-03-04 |
CO7101247A2 (es) | 2014-10-31 |
HK1203390A1 (en) | 2015-10-30 |
US20150140042A1 (en) | 2015-05-21 |
IN2014MN02359A (ru) | 2015-08-14 |
US20160296551A1 (en) | 2016-10-13 |
CA2866230C (en) | 2020-08-18 |
AU2013255885A1 (en) | 2014-09-25 |
CN104394846B (zh) | 2018-10-19 |
SG10201607288VA (en) | 2016-10-28 |
AU2013255885B2 (en) | 2017-10-05 |
MX2014013256A (es) | 2015-01-16 |
EP2846767B1 (en) | 2022-01-26 |
WO2013164380A1 (en) | 2013-11-07 |
US20180325939A1 (en) | 2018-11-15 |
RU2650636C2 (ru) | 2018-04-16 |
KR102240042B1 (ko) | 2021-04-14 |
KR20150008855A (ko) | 2015-01-23 |
CA2866230A1 (en) | 2013-11-07 |
NZ630040A (en) | 2016-10-28 |
JP6349304B2 (ja) | 2018-06-27 |
SG11201406208QA (en) | 2014-11-27 |
BR112014026957A2 (pt) | 2017-06-27 |
AU2013255885C1 (en) | 2018-04-26 |
BR112014026957A8 (pt) | 2018-01-16 |
ES2911116T3 (es) | 2022-05-17 |
US10485816B2 (en) | 2019-11-26 |
CL2014002929A1 (es) | 2015-01-16 |
US9987300B2 (en) | 2018-06-05 |
JP2015515968A (ja) | 2015-06-04 |
EP2846767A1 (en) | 2015-03-18 |
US9682096B2 (en) | 2017-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014148544A (ru) | Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей | |
EA201591729A1 (ru) | Пригодные для вдыхания агломераты частиц пористого носителя и тонкоизмельченного лекарственного средства | |
JP2014240439A5 (ru) | ||
EA201390409A1 (ru) | Составы с низкой дозой панкрелипазы и кишечно-растворимым покрытием | |
RU2016117398A (ru) | Композиции полиинозиновой-полицитидиловой кислоты (поли (и:ц)) для лечения инфекций верхних дыхательных путей | |
JP2015515968A5 (ru) | ||
EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
RU2014128291A (ru) | Гемостатический агент, способ остановки кровотечения и назальный спрей | |
JP2016535094A5 (ru) | ||
UA112540C2 (uk) | Плівкова лікарська форма, яка містить вільну основу силденафілу, і спосіб її отримання | |
PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
JP2015505541A5 (ru) | ||
EP2682101A3 (en) | Inhalation Compositions Comprising Glucose Anhydrous | |
EP2682098A3 (en) | Inhalation Compositions | |
WO2015001163A3 (es) | Nanopartículas lipídicas para la cicatrización de heridas | |
EP2682100A3 (en) | Inhalation Compositions Comprising Muscarinic Receptor Antagonist | |
EA201700182A1 (ru) | Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой | |
RU2017142710A (ru) | Состав полиинозиновой-полицитидиловой кислоты (поли-(i:с)) на основе горохового крахмала для профилактики и/или лечения инфекций верхних дыхательных путей | |
EP2682129A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Glucose Anhydrous | |
RU2011111666A (ru) | Препарат в форме пленки и способ его получения | |
WO2014043243A3 (en) | Platinum compounds, compositions and methods for the treatment of cancer | |
EP2682103A3 (en) | Compositions Comprising Muscarinic Receptor Antagonist and Sorbitol | |
JP2017517574A5 (ru) | ||
EA032385B9 (ru) | Фармацевтическая композиция для лечения заболеваний желудочно-кишечного тракта |